Article
First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.
Blood - 17 Sept 2026
Wang Michael, Hoffmann Marc, Wrobel Tomasz, Trneny Marek, Belada David, Demirkan Fatih, Panayiotidis Panayiotis, Jurczak Wojciech, Zinzani Pier Luigi, Keating Mary-Margaret, Yoon Sung-Soo, Egyed Miklós, Tam Constantine S, Johnson Nathalie A, Szafer-Glusman Edith, Lin Jennifer, Dean James P, Neuenburg Jutta K, von Keudell Gottfried
Abstract excerpt
ABSTRACT: The phase 3 SYMPATICO study included an open-label cohort to evaluate first-line ibrutinib plus venetoclax in patients with nonblastoid mantle cell lymphoma (MCL) aged ≥65 years (n = 65) or ≥18 years with a TP53 mutation (TP53m; n = 11). Eligible patients received oral ibrutinib 560 mg once daily and venetoclax (5-week ramp-up to 400 mg once daily) for 2 years, then single-agent ibrutinib 560 mg until...
Read the complete abstract on PubMedTopics
- Aged
- Aged, 80 and over
- Female
- Humans
- Male